Featured News
All News
Promising Memory-Like NK Cell Therapy Spurs Trial Expansion Available Only at Siteman Kids at St. Louis Children’s Hospital and Siteman Cancer Center
ST. LOUIS — Oncologists at WashU Medicine in St. Louis are expanding an ongoing stem cell transplant study that previously enrolled only patients in remission. The study — shown to be safe and effective and aimed at preventing relapse — now also includes patients with refractory disease and those
More Than 30 Countries Now Participate in Siteman Kids’ Pediatric Neuro-Oncology Tumor Boards
Collaborative Approach Enhances Care for Children with Brain Tumors and NF Worldwide An international pediatric brain tumor board established by Mohamed Shebl Abdelbaki, MD, WashU Medicine pediatric oncologist and director of the Pediatric Neuro-Oncology Program at Siteman Kids at St. Louis Children’s Hospital, is rapidly becoming a collaborative, global
Enrolling Now: ‘High Five’ Study Investigates Short-Term, High-Dose Radiation Therapy for High-Risk Prostate Cancer
A promising study evaluating the use of ultra-hypofractionation radiation therapy for the treatment of high-risk prostate cancer is underway at all six locations of Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. Called the “High Five” clinical trial, or NRG-GU-013, the phase III multicenter study will help determine
Immunotherapy improves survival of patients with locally advanced head and neck cancer
Approved drug that revolutionized melanoma treatment may change standard of care for yet another cancer type Research presented at the annual meeting of the American Association for Cancer Research (AACR) in April provides the strongest clinical evidence to date that standard of care therapy could soon be updated for the
New Phase 2 Clinical Trial Opens for Rare Leukemia/Lymphoma in Children
Off-the-shelf cellular therapy targets relapsed or refractory T-cell leukemia/lymphoma A potentially groundbreaking clinical trial is now open at Siteman Kids at St. Louis Children’s Hospital to evaluate an allogeneic, off-the-shelf cellular therapy designed to treat patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/LBL).
Vaccine Shows Promise Against Aggressive Breast Cancer
A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, the trial is the first to report results for this type
Promising Memory-Like NK Cell Therapy Spurs Trial Expansion Available Only at Siteman Kids at St. Louis Children’s Hospital and Siteman Cancer Center
ST. LOUIS — Oncologists at WashU Medicine in St. Louis are expanding an ongoing stem cell transplant study that previously enrolled only patients in remission. The study — shown to be safe and effective and aimed at preventing relapse — now also includes patients with refractory disease and those
More Than 30 Countries Now Participate in Siteman Kids’ Pediatric Neuro-Oncology Tumor Boards
Collaborative Approach Enhances Care for Children with Brain Tumors and NF Worldwide An international pediatric brain tumor board established by Mohamed Shebl Abdelbaki, MD, WashU Medicine pediatric oncologist and director of the Pediatric Neuro-Oncology Program at Siteman Kids at St. Louis Children’s Hospital, is rapidly becoming a collaborative, global
Enrolling Now: ‘High Five’ Study Investigates Short-Term, High-Dose Radiation Therapy for High-Risk Prostate Cancer
A promising study evaluating the use of ultra-hypofractionation radiation therapy for the treatment of high-risk prostate cancer is underway at all six locations of Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. Called the “High Five” clinical trial, or NRG-GU-013, the phase III multicenter study will help determine
Immunotherapy improves survival of patients with locally advanced head and neck cancer
Approved drug that revolutionized melanoma treatment may change standard of care for yet another cancer type Research presented at the annual meeting of the American Association for Cancer Research (AACR) in April provides the strongest clinical evidence to date that standard of care therapy could soon be updated for the
New Phase 2 Clinical Trial Opens for Rare Leukemia/Lymphoma in Children
Off-the-shelf cellular therapy targets relapsed or refractory T-cell leukemia/lymphoma A potentially groundbreaking clinical trial is now open at Siteman Kids at St. Louis Children’s Hospital to evaluate an allogeneic, off-the-shelf cellular therapy designed to treat patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/LBL).
Vaccine Shows Promise Against Aggressive Breast Cancer
A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, the trial is the first to report results for this type
Make a Referral
Refer a patient to a Washington University Physician at Siteman Cancer Center.
Physician Services
Contact our physician liaison team for more information about Siteman Cancer Center services, physicians and programs.
Subscribe to Our Newsletter
Receive the latest updates on Siteman Cancer Center services, physicians, educational programs and more.